United for Early Detection at the IKN Pink October Carnival 2024!

On 5th October 2024, Gene Solutions Malaysia had the honor of participating in the IKN Pink October Carnival 2024, an event dedicated to raising awareness and fostering a sense of community around cancer prevention and early detection. This year’s theme, “Living Well, Living Together,” captured the essence of unity, strength, and awareness, reminding us all of the power of prevention, early detection, and the impact of effective treatment.

The carnival was officiated by YAB Dato’ Sri Haji Fadillah bin Haji Yusof, Deputy Prime Minister, and was attended by YB Datuk Seri Dr. Dzulkefly Ahmad, Health Minister and YBrs. Dr. Mohd Anis bin Haron @ Harun, IKN Director.

One of the day’s highlights was a recognition from the Malaysia Book of Records for creating the largest pink ribbon formation with 2,050 participants, symbolising a unified commitment to the fight against cancer.

At the Gene Solutions Malaysia booth, our focus was on the vital role of early cancer detection. We focused on sharing the importance of early screening through our Multi-Cancer Early Detection (MCED) test, SPOT-MAS, which uses advanced ctDNA technology to detect early signals of 5 common and aggressive cancers. Our booth also provided an interactive experience for visitors, where they could take part in raising awareness by sharing photos and messages of support on social media, using hashtags like #earlydetection, #MCED, and #GeneSolutionsMalaysia.

The IKN Pink October Carnival was a profound reminder that through awareness, early detection, and collective action, we can make significant strides in the fight against cancer. Together, we continue to raise awareness, inspire action, and bring hope to the fight against cancer.

About Gene Solutions Malaysia

Gene Solutions established its operations and services in Malaysia in 2023 and is committed to provide the local community access to next-generation genetic tests that support reproductive health and clinical oncology. In the field of clinical oncology, personalized minimal residual disease (MRD) detection, and multi-cancer early detection (MCED) tests using advanced ctDNA technology are among some of the products available. Partnering with local laboratory partners Premier Integrated Lab and Innoquest Malaysia, Gene Solutions Malaysia is committed to enhancing healthcare with their innovative genetic solutions.

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More